Home › Targets › NTRK3
Radioligand therapy target profile

NTRK3: IHC Expression in Cancer and Radioligand Target Profile

neurotrophic receptor tyrosine kinase 3 · Ensembl ENSG00000140538 · Data updated 2026-11-01

NTRK3, neurotrophic receptor tyrosine kinase 3, is a cell-surface protein (RTK). In Human Protein Atlas immunohistochemistry, NTRK3 staining is highest in cervical cancer (64% of samples positive), colorectal cancer (64% of samples positive) and lymphoma (67% of samples positive). Evidence on whether NTRK3 internalizes is mixed. Clinical status: FDA-approved drug (any modality).

Is NTRK3 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze NTRK3 free
LocalizationCell-Surface
Top cancer (IHC)Cervical Cancer
InternalizationUncertain
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.84

Is NTRK3 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

NTRK3 IHC staining by cancer type

Protein expression of NTRK3 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Cervical Cancer0.27Medium64%
Colorectal Cancer0.24Medium64%
Lymphoma0.22Medium67%
Ovarian Cancer0.21Medium27%
Liver Cancer0.20Medium50%
Lung Cancer0.17Low38%
Prostate Cancer0.15Low27%
Bladder Cancer0.12Low36%
Glioma0.12Low36%
Skin Cancer0.11Low33%
Thyroid Cancer0.11Low33%
Testicular Cancer0.09Low27%
Kidney Cancer0.08Low25%
Neuroendocrine Tumors0.08Low25%
Breast Cancer0.06Low18%
Gastric Cancer0.06Low8%
Melanoma0.03Low9%
Pancreatic Cancer0.03Low8%

Not detected by IHC in: head and neck cancer, endometrial cancer.

Is NTRK3 internalized?

Uncertain. The abstract mentions regulation of genes involved in receptor endocytosis, but it does not provide direct evidence that NTRK3 itself undergoes internalization or endocytosis upon ligand or antibody binding.

Sources: PMID 25423262. AI-extracted from abstracts, so verify before citing.

NTRK3 clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for NTRK3 yet. Search ClinicalTrials.gov for NTRK3 trials.

NTRK3 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See NTRK3 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

NTRK3 gene essentiality (DepMap)

CRISPR knockout effect across 1250 cancer cell lines: 0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related cervical cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · CEA (CEACAM5) · Mesothelin (MSLN) · ITGB6 · ITGAV

See all radioligand therapy targets in cervical cancer.

See how NTRK3 ranks against 15,000 targets for your indication.

Analyze NTRK3 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is NTRK3 the right target for your program? · 5 free analyses, no card Analyze NTRK3 free